Li Ping, Gao Sihai, Jie Wei, Ao Qilin, Huang Yafei
Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Department of Thoracic and Cardiovascular Surgery, Tongji Hospital, Wuhan, 430030, China.
J Huazhong Univ Sci Technolog Med Sci. 2012 Apr;32(2):181-185. doi: 10.1007/s11596-012-0032-8. Epub 2012 Apr 20.
This study examined the effect of astilbin on the proliferation of rat aortic smooth muscle cells (RASMCs) induced by angiotensin II (AngII) and explored the possible mechanisms. Cell proliferation model of RASMCs was induced by treatmente with AngII. Cells were randomly divided to 8 groups. Normally cultured VSMCs serves as blank control group; in AngII model group, cells were treated with AngII at 10(-7) mol/L; in three astilbin groups, cells were treated with 10, 15, 30 mg/L of astilbin; in three AngII+astilbin groups, cells were treated with AngII (at 10(-7) mol/L) and astilbin at 10, 15, 30 mg/L. Cell proliferation ability was detected by MTT method and the cell cycles and proliferation index were flow cytometrically determined. The expression of c-myc mRNA was assessed by using reverse transcription polymerase chain reaction (RT-PCR), and the expression of NF-κB in RASMCs was immunocytochemically observed. Our results showed that MTT metabolism in RASMCs in the basic and AngII stimulated situation was inhibited by astilbin, and the cells numbers of G(0)/G(1) phase were increased and that of G(2)/S phase were decreased markedly. Not only highly expression of c-myc gene stimulated by AngII could be inhibited by Astilbin significantly, but also the expression of NF-κB protein can be down regulated by Astilbin. We are led to conclude that astilbin astilbin can inhibit the AngII-mediated proliferation of RASMCs by blocking the transition of RASMCs from G(0)/G(1) phase to S phase and by down-regulating the expression of NF-κB, c-myc gene.
本研究检测了落新妇苷对血管紧张素II(AngII)诱导的大鼠主动脉平滑肌细胞(RASMCs)增殖的影响,并探讨其可能机制。采用AngII处理诱导RASMCs细胞增殖模型。细胞随机分为8组。正常培养的血管平滑肌细胞作为空白对照组;AngII模型组细胞用10⁻⁷mol/L的AngII处理;落新妇苷三个剂量组细胞分别用10、15、30mg/L的落新妇苷处理;AngII+落新妇苷三个剂量组细胞用10⁻⁷mol/L的AngII和10、15、30mg/L的落新妇苷处理。采用MTT法检测细胞增殖能力,流式细胞术检测细胞周期及增殖指数。采用逆转录聚合酶链反应(RT-PCR)检测c-myc mRNA的表达,免疫细胞化学法观察RASMCs中NF-κB的表达。结果显示,落新妇苷在基础状态及AngII刺激情况下均抑制RASMCs的MTT代谢,G(0)/G(1)期细胞数增加,G(2)/S期细胞数明显减少。落新妇苷不仅能显著抑制AngII刺激引起的c-myc基因高表达,还能下调NF-κB蛋白表达。由此得出结论,落新妇苷可通过阻断RASMCs从G(0)/G(1)期向S期的转变以及下调NF-κB、c-myc基因表达来抑制AngII介导的RASMCs增殖。